Could Moderna/Merck Cancer Vaccine Succeed Where Others Have Flopped?
Executive Summary
The partners unveiled long-awaited proof-of-concept data for mRNA-4157 at the AACR meeting showing a statistically significant improvement in recurrence-free survival among melanoma patients.
You may also be interested in...
Moderna Shows Ambition With Flu Success And Cancer Therapy Expansion
Slower COVID-19 vaccine sales will see Moderna’s revenues decline this year, but the company is investing heavily to speed a new wave of therapies to the market.
Moderna and CARsgen Look For Synergies In CAR-T And Cancer Vaccine Combo
While Astellas is closing in on the first Claudin18.2 antibody therapy cancer approval, CARsgen and Moderna aim to boost responses from a CAR-T approach.
Rise In COVID-19 Numbers Won’t Solve Moderna’s Slump
Moderna is suffering from a slump in sales of its COVID-19 vaccine, and investors remain skeptical about its chances of hitting anywhere near those blockbuster heights with its next wave of products.